Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Lung Neoplasms 5Triple Negative Breast Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Uterine Cervical Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Camurati-Engelmann Syndrome 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Microsatellite Instability 1Metastatic Solid Tumors 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Trastuzumab 243Paclitaxel 193Cyclophosphamide 158Docetaxel 134Letrozole 113Capecitabine 113Fulvestrant 106Doxorubicin 103Bevacizumab 87Carboplatin 81exemestane 80Anastrozole 79Lapatinib 70Tamoxifen 69Albumin-Bound Paclitaxel 57palbociclib 54pertuzumab 53Taxes 51Gemcitabine 50Radiotherapy 46eribulin 43pembrolizumab 41Everolimus 41Ado-Trastuzumab Emtansine 41Vinorelbine 38130-nm albumin-bound paclitaxel 35ixabepilone 32Epirubicin 28pegfilgrastim 25liposomal doxorubicin 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Breast Neoplasms × bintrafusp alfa protein, human × Clear all
NCT04489940 2023-04-10

Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

EMD Serono

Phase 2 Terminated
11 enrolled 9 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 10 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡